Immunovant Inc. (IMVT) stock declines during after-hour, given no current update.

KOF Stock
KOF Stock

Immunovant Inc. (NASDAQ: IMVT) stock gained by 3.89% at last close whereas the IMVT stock-price plunge by 6.46% in the after-hours trading session. Immunovant, Inc. is a medical pharmaceutical business dedicated to helping people with autoimmune illnesses live normal lives. IMVT-1401, a unique, totally human anti-FcRn monoclonal antibody, is being developed by Immunovant as a subcutaneous injection for the cure of autoimmune disorders caused by pathogenic IgG antibodies.

>> 7 Top Picks for the Post-Pandemic Economy << 

IMVT stock’ Recent Development

Renee Barnett has been hired as Chief Financial Officer of Immunovant, beginning October 4, 2021. Ms. Barnett made her debut in healthcare with Eli Lilly, where she gained expertise in strategic finance leadership throughout the drug development life cycle. She served as the CFO of Lilly Austria and Switzerland, as well as the international lead for Financial Planning and Analysis, throughout her time at Lilly. Ms. Barnett most recently worked at AbleTo, Inc. which is an innovation healthcare service provider centered on virtual delivery of behavioral healthcare, in a range of executive leadership roles. Ms. Barnett has a Harvard Business School MBA and a DePauw University BA in Physics.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Read More

Ms. Barnett enters Immunovant as the business prepares to launch a major study in myasthenia gravis (MG), as well as relaunch its thyroid eye disease (TED) and warm autoimmune hemolytic anaemia projects (WAIHA). Based on regulatory alignment, the company also intends to start trials in two other indications.


Ms. Barnett. stated that he is happy to be a part of Immunovant team at such an interesting and vital time, as the company harnesses its strong financial position to continue batoclimab research across various indications, with many prospects to assist individuals with autoimmune illnesses live normal lives.

>> 7 Top Picks for the Post-Pandemic Economy << 

Pete Salzmann, Chief Executive Officer commented,

Renee Barnett has joined the Immunovant executive team at a significant time for the company. Renee has extensive experience in medication development as well as strategic finance management. Over the course of her career, she has consistently generated great outcomes and thrives in fast-paced, high-growth environments. Renee’s wealth of financial and executive skills will be crucial as their team grows and they speed the production of batoclimab (IMVT-1401).


Please enter your comment!
Please enter your name here